Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. (TSXV: GSD, OTCQB: DVHGF) is a clinical stage pharmaceutical and biopharmaceutical company that regularly issues news related to its development of prescription drugs for auto-immune inflammatory and fibroinflammatory diseases. As a medicinal and botanical manufacturing company with a focus on prescription botanical drug products, its updates often center on scientific progress, clinical programs and corporate developments.
News coverage for Devonian frequently highlights advances with its lead candidate Thykamine™, the first pharmaceutical product from its SUPREX™ platform. Releases have described comparative in vitro studies against widely used anti-inflammatory drugs, in vivo work in models of MASH and fibrosis, and Phase II clinical data in ulcerative colitis and atopic dermatitis. The company also reports on patent filings, new potential indications and formulation work, such as development of oral forms for gastrointestinal diseases.
Investors and observers can also expect regular financial and corporate news. Devonian publishes quarterly and annual financial results, including commentary on distribution revenues generated by its Altius commercialization subsidiary and on how those revenues support Thykamine™ development. Other announcements cover private placements, stock option grants, changes in officers and directors, shareholder meeting results, option and rights plans, and matters related to financial reporting and exchange approvals.
Because Devonian operates at the intersection of clinical-stage drug development and pharmaceutical distribution in Canada, its news flow combines R&D milestones, regulatory and intellectual property updates, and capital markets activity. Following the DVHGF news stream can help readers track the evolution of its botanical-based pipeline, the status of distribution agreements managed through Altius, and key corporate decisions that shape the company’s long-term strategy.
Devonian (OTCQB: DVHGF) reported Feb 19, 2026 preclinical human liver-on-a-chip results showing dose-dependent anti-fibrotic and anti-inflammatory activity for Thykamine™. In a 14-day PhysioMimix® MASH model, Thykamine reduced fibrosis biomarkers, Type I collagen deposition and lowered IL-6/IL-8, with strongest effects at 0.1–0.2 mg/mL.
LDH remained low (no drug-induced liver injury signal). Company plans additional preclinical studies to further characterize disease-modifying potential in MASH and other fibrotic diseases.
Devonian (OTCQB: DVHGF) announced that a proprietary Thykamine™ fingerprint has been filed in two patent applications and will be used in all future Thykamine filings. The fingerprint defines eight chemical components in precise ratios using HPLC‑MS, with NMR confirmation showing ≥98% batch‑to‑batch confidence.
Biological potency assays in a U‑937 human cell model demonstrated equivalent activity across batches, including consistent inhibition of inflammatory cytokines RANTES and MIP‑1β. The fingerprint, NMR, and potency assays are being integrated into Thykamine's CMC framework to support pharmaceutical development and regulatory preparedness.
Devonian (OTCQB: DVHGF) reported additional preclinical molecular data from its STAM mouse MASH study showing dose-dependent anti-MASH, anti-inflammatory and anti-fibrotic gene effects for Thykamine.
Oral dosing at 0.5, 5.0 and 50.0 mg/kg once daily for three weeks down‑regulated 29 fibrosis/inflammation genes, with several genes reduced by approximately 80–90% versus placebo and regional liver‑lobe differences observed.
Devonian Health (OTCQB: DVHGF) reported positive preclinical results for Thykamine in a bleomycin-induced pulmonary fibrosis mouse model on Feb 10, 2026. Thykamine, given orally at doses including 0.5 mg/kg, produced statistically significant reductions in lung wet weight, fibrosis (Ashcroft) and inflammation versus bleomycin controls.
Gene expression changes included downregulation of Fn1, Col1a1, Col3a1, Col6a1/3, Birc5, Ccl2, Cxcl2 and increased Mmp9 with reduced Mmp13, suggesting controlled matrix remodeling and antifibrotic activity. Pirfenidone at 220 mg/kg did not reach significance on physiological endpoints.
Devonian Health Group (OTCQB: DVHGF) appointed Dennis Turpin as Chief Financial Officer effective February 2, 2026; he will remain on the board and previously chaired the audit committee. The company granted Mr. Turpin 25,000 options vesting immediately at an $11.50 exercise price for 10 years.
The company corrected prior option disclosures: a pre-consolidation exercise price was revised from $0.18 to $0.19, then adjusted to $11.40 post-consolidation after a 1-for-60 share consolidation on January 22, 2026; option counts were rounded down per the plan.
Devonian Health Group (OTCQB: DVHGF; TSXV: GSD) announced a 1-for-60 share consolidation, approved by shareholders with 99.79% support, as part of preparations for a potential U.S. listing. The consolidation is subject to final TSXV acceptance and is expected to take effect at market open on or around January 22, 2026. Post-consolidation the company expects approximately 2,765,725 common shares outstanding (from 165,943,512 today), with no fractional shares issued and rounding to the nearest whole share. The OTCQB symbol will temporarily append a "D" for 20 business days after effectiveness. New CUSIP 251834883 and ISIN CA2518348834 will apply.
Devonian Health Group (OTCQB: DVHGF) announced on December 19, 2025 that its Board approved grants of stock options totaling 3,434,006 options. The grants consist of 2,948,056 options to directors and a consultant (including 2,798,056 to directors), 385,950 to employees as performance/retainer awards, and 100,000 to an R&D consultant.
The options are exercisable at $0.18 per share, expire 10 years from the grant date, and vest 25% on grant then 25% per year for three years.
Devonian Health Group (OTCQB: DVHGF) announced on December 4, 2025 the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." Researchers compared Thykamine™ with six widely prescribed anti-inflammatory drugs in an in vitro immune-activated cell model and reported that Thykamine™ inhibited MCP-1, MIP-1α and MIP-1β with greater potency than all comparators and suppressed RANTES comparable or superior to most agents tested. Effects occurred at lower concentrations and with no detectable cytotoxicity, suggesting a favorable tolerability profile and potential for further therapeutic development targeting chronic inflammatory and fibrotic conditions.
Devonian Health Group (OTCQB: DVHGF) reported fourth-quarter and fiscal 2025 results for the year ended July 31, 2025. Key metrics: Q4 distribution revenue $1.3M (down 87% YoY), FY distribution revenue $23.6M (up 22% YoY), Q4 net loss $0.375M ($0.003/share), and FY net loss $6.0M ($0.041/share). The FY loss included a $4.6M goodwill impairment and $0.2M IP impairment. R&D spending rose to $2.0M (up 55.8%) to support Thykamine pediatric phase 2/3 and preclinical work. The corporation is debt free after repaying $2.2M and held $7.0M cash at July 31, 2025. Pierre Labbé was appointed to the board.
Devonian Health Group (OTCQB: DVHGF), a clinical-stage biopharmaceutical company, provided updates on multiple fronts. The company reported significant progress with its flagship drug Thykamine™, validating batch-to-batch consistency through advanced analytical techniques and advancing pre-clinical programs in MASH and pulmonary fibrosis, with data expected in fall 2025.
The company is developing oral formulations for Thykamine™ and received positive U.S. dermatologist survey results for pediatric atopic dermatitis applications. Additionally, Devonian announced the upcoming termination of its Pantoprazole Magnesium distribution agreement in April 2026, which represented 10.6% of FY2024 revenues and 4.2% of revenue for the nine months ended April 2025.
The company also corrected details of its recent private placement, noting total gross proceeds of $2.36 million through the issuance of 15.75 million units at $0.15 per unit, each including one share and one warrant exercisable at $0.20 for 24 months.